imlygic
amgen europe b.v. - talimogen laherparepvec - melanom - antineoplastiske midler - imlygic er indiceret til behandling af voksne med inoperabel modermærkekræft, regionalt eller fjernt metastatisk (stadie iiib, iiic og ivm1a) med ingen ben, hjerne, lunge eller andre visceral sygdom.
scenesse
clinuvel europe limited - afamelanotide - protoporphyria, erytropoietisk - emollients og protectives - forebyggelse af fototoksicitet hos voksne patienter med erytropoietisk protoporphyria (epp).
proleukin 18 mill. ie pulver til injektions-/infusionsvæske, opløsning
novartis healthcare a/s - aldesleukin - pulver til injektions-/infusionsvæske, opløsning - 18 mill. ie
lamotrigin "aristo" 25 mg tabletter
aristo pharma gmbh - lamotrigin - tabletter - 25 mg
losartan "jubilant" 100 mg filmovertrukne tabletter
jubilant pharmaceuticals nv - losartankalium - filmovertrukne tabletter - 100 mg
losartan "jubilant" 50 mg filmovertrukne tabletter
jubilant pharmaceuticals nv - losartankalium - filmovertrukne tabletter - 50 mg
litfulo
pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunosuppressiva - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
seedron suspensionskoncentrat
adama northern europe b.v. - tebuconazol, fludioxonil - suspensionskoncentrat - 10 g/l tebuconazol ; 50 g/l fludioxonil
yervoy
bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastiske midler - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 og 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.